Abstract：
Monoclonal gammopathy of renal significance (MGRS) is a hemato-nephrological term referring to a heterogeneous group of kidney disorders characterized by direct or indirect kidney injury caused by a monoclonal immunoglobulin (MIg) produced by a B cell or plasma cell clone that does not meet current hematologic criteria for therapy. MGRS-associated kidney diseases are diverse and can result in the development of end stage kidney disease (ESKD). The diagnosis is typically made by nephrologists through a kidney biopsy. Many distinct pathologies have been identified and they are classified based on the site or composition of the deposited Mig, or according to histological and ultrastructural findings. Therapy is directed towards the identified underlying clonal population and treatment decisions should be coordinated between hematologists and nephrologists in a multidisciplinary fashion, depend on the type of MGRS, the degree of kidney function impairment and the risk of progression to ESKD.
摘要：
肾脏意义上的单克隆丙种球蛋白病（MGRS）是一个血液肾病术语，是指一组异质性的肾脏疾病，其特征是由B细胞或浆细胞克隆产生的单克隆免疫球蛋白（MIg）引起的直接或间接肾损伤不符合当前的血液学治疗标准。MGRS相关的肾脏疾病是多种多样的，并且可以导致终末期肾脏疾病（ESKD）的发展。通常由肾脏病学家通过肾活检进行诊断。已经确定了许多不同的病理，并根据沉积的Mig的部位或组成对其进行分类。或根据组织学和超微结构的发现。治疗针对已确定的潜在克隆人群，血液学家和肾脏病学家之间应以多学科的方式协调治疗决策。取决于MGRS的类型，肾功能损害的程度和进展为ESKD的风险。
